SB Management Ltd
CIK
1818296
Location
ABU DHABI, C0
Portfolio Value
Micro
$92,865,488
Diversification
Highly concentrated
Filing Date
Global Rank
#4,687
/ 6,760
▼ 2128
Top Industry
Biotechnology
81.5%
3Y Alpha vs SPY
-36.6%
Period ended 4 years ago
Filed May 16, 2022 · 4y
7 quarters · since Sep 2020
Clone Performance
Jun 2023–Jun 2026 · vs SPYHypothetical growth of cloning every reported 13F position and rebalancing on each filing, indexed to the same start.
Cloned portfolio
-40.4%
SPY
+76.3%
Annualised alpha
-36.6%
Max drawdown
−78.5%
Estimate. 13F holdings are quarter-lagged and long-only, so the clone rebalances about 45 days after each period end — when the filing becomes public — and excludes options and short positions. Past performance does not predict future results.
Portfolio Concentration
2 positions · as of Mar 31, 2022 · Δ vs Dec 31, 2021Top Position
81.5%
+32.8 pts
Top 5
100.0%
0.0 pts
Top 10
100.0%
0.0 pts
HHI
6,987
Highly concentrated+2,826
Portfolio Trend
7 quarters · across all stocks
Sector Breakdown
As of Mar 31, 2022| Sector | % Portfolio | Value |
|---|---|---|
| Healthcare | 100.0% | $92,865,488 |
Last Quarter's Activity
Export CSVAdded To
Positions the filer increasedNo qualifying positions this quarter.
New Positions
Positions the filer opened this quarterNo qualifying positions this quarter.
2 positions ·
$92,865,488 total
· as of Mar 31, 2022
| Ticker | Company | Type | Shares | Value (USD) | % of Portfolio | History |
|---|---|---|---|---|---|---|
| ABCL |
AbCellera Biologics Inc.
Healthcare
|
Reduced | 7,764,299 | $75,701,915 | 81.52% | |
| PACB |
Pacific Biosciences Of California, Inc.
Healthcare
|
Reduced | 1,886,107 | $17,163,573 | 18.48% |